FDA Grants Accelerated Approval to AVLAYAH, a BBB-Penetrating Biologic, Ushering in a New Era for Brain Drug Delivery

Drug Delivery Leader USA

Overview

On March 25, 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), the first biologic engineered to traverse the blood-brain barrier (BBB). This landmark decision, following decades of research and building on the 2021 approval of pavinafusp alfa in Japan, validates receptor-mediated transcytosis as a viable drug delivery pathway. The approval opens new therapeutic avenues for debilitating central nervous system disorders like Alzheimer’s and Parkinson’s disease, marking a significant breakthrough in overcoming a long-standing challenge in medicine.

In Depth

Background

Central Nervous System (CNS) disorders represent an area of immense unmet medical need, yet effective drug development has been severely hampered by the formidable physical and biochemical barrier of the Blood-Brain Barrier (BBB). While the BBB plays a vital role in protecting the brain from harmful substances, it simultaneously obstructs the passage of many promising therapeutic agents. Historically, CNS drugs often had limited efficacy or caused systemic side effects due to their inability to cross the BBB effectively. The accelerated approval of AVLAYAH signals a new era where drug delivery to the brain is “no longer impossible,” holding the potential to revolutionize treatment strategies for CNS diseases worldwide.

Key Findings

On March 25, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AVLAYAH (generic name: tividenofusp alfa-eknm), a groundbreaking biologic specifically engineered to traverse the blood-brain barrier (BBB). This approval culminates decades of intensive research, signifying a critical breakthrough in overcoming the long-standing challenge of drug delivery for central nervous system (CNS) disorders. AVLAYAH is designed to efficiently cross the BBB by utilizing a receptor-mediated transcytosis (RMT) pathway, a cellular process that allows cells to internalize substances via specific receptors, transport them across the cell, and release them on the opposite side, thereby enabling large molecules to enter the brain.

This latest approval follows the 2021 approval of a similar drug, pavinafusp alfa, in Japan, indicating a growing international validation of the RMT pathway as a safe and effective strategy for drug delivery to the brain. The BBB is a highly selective barrier that protects the brain from harmful substances in the circulating blood, but it has historically impeded the entry of most therapeutic agents, especially large biologics. AVLAYAH’s approval signifies the practical realization of technology capable of specifically breaching this barrier. While the specific target disease and detailed mechanism of this therapy are not elaborated upon, the ability to cross the BBB is paramount for treating neurodegenerative diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors. This advancement is expected to catalyze further research and development efforts in CNS therapeutics, focusing on optimal brain shuttles, targets, and patient populations, and is projected to boost investment in the CNS sector by global pharmaceutical companies, fostering the creation of untapped therapeutic markets and offering new hope for patients worldwide.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime